Efficacy and safety of leflunomide in psoriatic arthritis


  • ATM Asaduzzaman
  • Akramullah Sikder
  • Md. Mostaque Mahmud
  • Harashit Kumar Pau
  • Md. Nazrul Islam


Psoriasis, psoriatic arthritis, leflunomide, methotrexate


Objective To compare the effectiveness and safety of leflunomide with methotrexate (MTX) in the treatment of psoriatic arthritis. Methods An open, randomized clinical trial was conducted in 32 patients of psoriatic arthritis at the department of Dermatology and Venereology and Rheumatology wing of Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh, from June 2002 to December 2003. 17 patients of leflunomide group were treated with oral leflunomide l00 mg for first three days followed by 20 mg daily. 15 patients of MTX group were treated with methotrexate 10 mg weekly. Both groups were allowed to take ibuprofen, maximum 1400 mg daily. For both groups hematological and biochemical tests were done at baseline and at every follow-up. All patients were assessed clinically for articular features, psoriasis area and severity index (PASI) for effectiveness and for side effects of drugs was listed for safety measure. Results Sixteen patients of leflunomide group and 14 of MTX group completed 24 weeks follow-up. Male: female ratio was 14:2, in leflunomide and 13:1 in MTX group. Significant improvement was observed in tender joint count, swollen joint count, joint tenderness index, NSAIDs score and PASI score in both groups. Adverse effects in both groups were tolerable and did not require any withdrawal or dose reduction. Asthenia, alopecia, nausea and vomiting were common side effects noticed by patients but overall there was no significant difference in between two groups. Conclusion Leflunomide appears to be as effective and safe as methotrexate in psoriatic arthritis. 


Shbeeb M, Uramoto KM, Gibson LE et al. The epidemiology of psoriatic arthritis in Olmsted County, Minnesota, USA, 1982-1991. J Rheumatol. 2000; 27:1247–50.

National Psoriasis Foundation. New research shows 1 million U.S. adults suffer from psoriatic arthritis: others may be at risk but not know it. Portland (OR): NPF Press Releases; May 15, 2002. URL:http://www.psoriasis.org/release2002.psasurvey.htm.

Tassiulas I, Duncan SR, Centola M et al. Clonal characteristics of T cell infiltrates in skin and synovium of patients with psoriatic arthritis. Hum Immunol. 1999;60:479-91.

Costello PJ, Winchester RJ, Curran SA et al. Psoriatic arthritis joint fluids are characterized by CD8 and CD4 T cell clonal expansions that appear antigen driven. J Immunol. 2001;166:28:78-86.

Jones G, Crotty M, Brooks P. Interventions for treating psoriatic arthritis (Cochrane Review). In: The Cochrane Library, Issue 3. Oxford: Update Software; 2001.

Black RL, O’Brien WM, Van Scott EJ et al. Methotrexate therapy in psoriatic arthritis. JAMA. 1964;189:743-7.

Antoni C, Dechant C, Hanns-Martin Lorenz PD et al. Open-label study of infliximab treatment for psoriatic arthritis: clinical and magnetic resonance imaging measurements of reduction of inflammation. Arthritis Care Res. 2002;47:506-12.

Mease PJ, Goffe BS, Metz J et al. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet. 2000;356:385-90.

Kraan MC, van Kuijk AW, Dinant HJ et al. Alefacept treatment in psoriatic arthritis: reduction of the effector T cell population in peripheral blood and synovial tissue is associated with improvement of clinical signs of arthritis. Arthritis Rheum. 2002;46:2776-84.

Breedveld FC, Dayer JM. Leflunomide: mode of action in the treatment of rheumatoid arthritis. Ann Rheum Dis. 2000;59:841-9.

Smolen JS, Kalden JR, Scott DL et al. Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomized, multicentre trial. Lancet. 1999;353:259-66.

Strand V, Cohen S, Schiff M et al. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Arch Intern Med. 1999;159:2542-50.

Clegg DO, Reda DJ, Mejias E et al. comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis. Arthritis Rheum. 1996;39:2013-20.

Fredriksson T, Petterson U. severe psoriasis- oral therapy with new retinoids. Acta Dermatologica. 1978;157:238-44.

Schiff MH, Strand V, Oed C, Loew-Friendrich I. Leflunomide: efficacy and safety in clinical trials for the treatment of rheumatoid arthritis. Drugs Today. 2000;36:383-94.

Spadaro A, Riccieri VA, Sili-scavalli et al. Comparison of cyclosporine A and methotrexate in the treatment of psoriatic arthritis: a one year prospective study. Clin Exp Rheumatol. 1995;13:589-93.

Zachariae H, Zachariae E. Methotrexate: treatment of psoriatic arthritis. Acta Derm Venereol. 1987;67:270-3.




How to Cite

Asaduzzaman A, Sikder A, Mahmud MM, Pau HK, Islam MN. Efficacy and safety of leflunomide in psoriatic arthritis. J Pak Assoc Dermatol [Internet]. 2016Nov.29 [cited 2024Jul.13];24(1):51-6. Available from: http://www.jpad.com.pk/index.php/jpad/article/view/174



Original Articles

Most read articles by the same author(s)